To the full analysis
Zhangzhou Pientzehuang Pharmaceutical. stock: growth
600436.SSZhangzhou Pientzehuang Pharmaceutical. reported $1.35B in revenue for fiscal 2025, down 16.6% on the prior year, up 6.7% a year on average over up to five years.
Daily figure as of 13 Nov 2026
Revenue (Annual rate)
16.2%
per year from 2006 to 2025, per share 15.9%
Earnings (Annual rate)
18.8%
per year from 2006 to 2025, per share 18.6%
Free cash flow (Annual rate)
no data
Growth per year by period
What reaches shareholders is growth per share: buybacks lift it, new shares dilute it.
| since 2020 | since 2015 | since 2006 | |
|---|---|---|---|
| Revenue | 6.7% | 16.9% | 16.2% |
| Revenue per share | 6.7% | 17.0% | 15.9% |
| Earnings | 5.2% | 16.6% | 18.8% |
| Earnings per share | 5.3% | 16.6% | 18.6% |
| Free cash flow | no data | no data | no data |
| Free cash flow per share | no data | no data | no data |
Fiscal years at a glance
How revenue and earnings grow
- Revenue
- Earnings
- Free cash flow
Figures as a table
| Year | Revenue | Earnings | Free cash flow |
|---|---|---|---|
| 2006 | $78.31M | $12.28M | $6.3M |
| 2007 | $88.94M | $14.27M | −$6.96M |
| 2008 | $97.44M | $21.13M | −$6.89M |
| 2009 | $104.19M | $19.44M | $14.97M |
| 2010 | $130.07M | $29.11M | $24.97M |
| 2011 | $153.2M | $38.22M | $29.6M |
| 2012 | $175.63M | $52.27M | $1.08M |
| 2013 | $209.33M | $64.45M | $19.16M |
| 2014 | $218.03M | $65.81M | $35.79M |
| 2015 | $282.78M | $69.98M | $33.99M |
| 2016 | $346.26M | $80.4M | $45.52M |
| 2017 | $556.96M | $121.02M | $93.74M |
| 2018 | $714.75M | $171.4M | $80.69M |
| 2019 | $858.14M | $206.11M | −$141.69M |
| 2020 | $976.38M | $250.67M | $157.17M |
| 2021 | $1.2B | $364.7M | $55.5M |
| 2022 | $1.3B | $370.76M | $1B |
| 2023 | $1.51B | $419.5M | $309.64M |
| 2024 | $1.62B | $446.44M | $36.8M |
| 2025 | $1.35B | $323.72M | −$39.41M |
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Currency
- Amounts in US dollars, converted at the ECB reference rate of 12 Nov 2026 ($1 = CN¥6.6683)
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Neutral, published since 7 Nov 2026 (in the score history since 3 Oct 2025)
- Valuation signal Fairly valued since 7 Nov 2026, previously Overvalued
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.